Wedbush Securities’s Trinity Biotech TRIB Stock Holding History

Wedbush Securities’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-93	Closed	-$31K	–	1018
2020 Q2	$31K	Buy	+93	New	+$21.3K	﹤0.01%	930
2019 Q1	–	Sell	-79	Closed	-$27K	–	953
2018 Q4	$27K	Sell	79 -29	-27%	-$13.4K	﹤0.01%	809
2018 Q3	$65K	Sell	108 -3	-3%	-$1.96K	0.01%	862
2018 Q2	$83K	Sell	111 -9	-8%	-$6.5K	0.01%	820
2018 Q1	$93K	Sell	120 -41	-25%	-$33.6K	0.01%	757
2017 Q4	$123K	Sell	161 -25	-13%	-$19.3K	0.02%	777
2017 Q3	$156K	Sell	186 -3	-2%	-$2.51K	0.02%	744
2017 Q2	$170K	Sell	189 -7	-4%	-$5.95K	0.02%	732
2017 Q1	$175K	Buy	196 +108	+123%	+$101K	0.02%	712
2016 Q4	$91K	Buy	+88	New	+$90.9K	0.01%	748

Other funds holding TRIB

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Wedbush Securities's TRIB Position: Q3 2020 in Review

Wedbush Securities sold out of Trinity Biotech (TRIB) in Q3 2020, closing a stake of 93 shares — an estimated $31K sold.

Wedbush Securities first reported a position in TRIB in Q4 2016 and held it in 10 quarters. The position peaked at $175K in Q1 2017. 23 funds tracked by Wall St. Rank hold TRIB as of Q3 2020.

Wedbush Securities reported no remaining Trinity Biotech position as of Q3 2020 after selling out during the quarter.
Wedbush Securities sold 93 Trinity Biotech shares in Q3 2020, an estimated $31K.
Wedbush Securities first reported a position in Trinity Biotech in Q4 2016 and held it in 10 quarters.
Wedbush Securities's Trinity Biotech position peaked at $175K in Q1 2017.
23 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2020.

Based on Wedbush Securities's 13F filing for Q3 2020, filed 20 Oct 2020.